Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Abstract Text:

Gina G Sleilati,Todd Leff,John W Bonnett,Robert A Hegele,Gina G Sleilati,Todd Leff,John W Bonnett,Robert A Hegele,Gina G Sleilati,Todd Leff,John W Bonnett,Robert A Hegele,

OBJECTIVE: To evaluate the effectiveness and safety of pioglitazone therapy in a patient with an atypical presentation of partial lipodystrophy. METHODS: We present a case report and review the associated literature to put this case in perspective and explain its atypical features. RESULTS: A 40-year-old woman was referred because of uncontrolled diabetes and dyslipidemia, despite receiving a total daily dose of insulin of 300 U and combination therapy with a statin and a fibrate. On examination, the patient was found to have substantial central and abdominal fat deposition in conjunction with slender arms and legs. The addition of pioglitazone to her therapeutic regimen resulted in a dramatic improvement in glycemic control and in the dyslipidemia. During approximately a 2-year period, the patient's insulin dose was decreased and was ultimately discontinued. Considerable increases in weight and in waist circumference were observed during this period. Sequencing of candidate genes known to be associated with familial partial lipodystrophy, acquired partial lipodystrophy, and generalized lipodystrophy showed no genetic abnormalities. Magnetic resonance imaging confirmed the presence of significant visceral and subcutaneous abdominal fat deposition, in association with scant fat tissue in the extremities. Her weight decreased after discontinuation of the insulin therapy and institution of dietary counseling. CONCLUSION: Thiazolidinediones have been shown to be efficacious in syndromic lipodystrophies, such as familial partial lipodystrophy subtype 2. We report that these pharmaceutical agents may also help improve metabolic variables in atypical lipodystrophy syndromes with no obvious molecular basis. A pronounced weight gain might result from synergism between thiazolidinediones and insulin promoting adipogenesis, which diminished somewhat after discontinuation of insulin therapy.

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Publishing Authors By Initials

GG Sleilati,T Leff,JW Bonnett,RA Hegele,GG Sleilati,T Leff,JW Bonnett,RA Hegele,GG Sleilati,T Leff,JW Bonnett,RA Hegele,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2007 Nov-Dec

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Endocrine practice : official journal of the Ameri

VOLUME: 13

Page Numbers: 656-61

Journal Abbreviation:

ISSN: 1934-2403

DAY: 23

MONTH: 10

YEAR: 2007

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9607439

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.

AFFILIATION: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Endocr Pract

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome Related Publications

• A Glimpse at HDL-based Therapy for Atherosclerosis.
• Abetalipoproteinemia: two case reports and literature review.
• Adaptation to visuomotor rotations in younger and older adults.
• Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.
• Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.
• Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population.
• Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.
• Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
• Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
• Emerging antidyslipidemic drugs.
• GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
• Gene-environment interactions in atherosclerosis.
• Gene-environment interactions in atherosclerosis: animal models.
• Genetic determinants of plasma lipoproteins.
• Genetics of metabolic syndrome.
• Genetics of metabolic syndrome: is there a role for phenomics?
• HIV-associated dyslipidaemia: pathogenesis and treatment.
• Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
• Human hepatocyte nuclear factor-1 beta (HNF1B) 1968A/G polymorphism.
• Is raising HDL a futile strategy for atheroprotection?
• Lipoprotein (a): an emerging risk factor for atherosclerosis.
• Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
• Lipoprotein(a) and fibrinolysis.
• Lipoprotein(a): biochemistry and genetics.
• Microsomal triglyceride transfer protein inhibition-friend or foe?
• Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum.
• Phenomics, lamin A/C, and metabolic disease.
• Single nucleotide polymorphisms of the fukutin gene.
• Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).
• The failure of torcetrapib: what have we learned?